|
Robert J. Spiegel, M.D., FACP, is Chief Medical Officer and senior vice president at Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation. Dr. Spiegel has direct responsibility for Global Pharmacovigilance and Clinical Quality Management systems.
He is chair of Schering-Plough's Clinical & Preclinical Safety Surveillance Committee (CPSSC). Prior to his current position, Dr. Spiegel was senior vice president, Clinical Research.
Dr. Spiegel has published more than 70 scientific papers and serves on the board of directors of Cancer Care, Inc. and the Cancer Institute of New Jersey. He has special research interest in biological approaches to cancer therapy. Dr. Spiegel received a B.A. at Yale University and an M.D. at the University of Pennsylvania. He completed a fellowship in medical oncology at the National Cancer Institute, NIH. Before joining Schering Corporation in 1983, he served as director of the Developmental Therapeutics Program at New York University Cancer Center and as assistant professor at New York University Medical Center (Department of Medicine). He remains an adjunct assistant professor at NYU.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
| 